Specialty Pharmacy

Study examining the metabolic pathway points to existing therapies that may slow the growth of small cell lung cancer.

Officials with the FDA have approved elagolix (Orilissa, AbbVie), a product specifically developed for women with moderate to severe endometriosis pain.

Adding acetazolamide to chemotherapy temozolomide for glioblastoma increased sensitivity to treatment and improved survival in animal models.

Study establishes increased risk of all-site cancer for both men and women with diabetes, but the excess risk of cancer is greater for women.

A recent systematic review and meta-analysis found that men with advanced cancers respond better than women to treatment with anti-PD-1 or anti-CTLA-4 immune checkpoint inhibitors.

Taking advantage of cost-effective generic medications can improve access to hepatitis B treatment, especially in countries with a high disease burden.

Top news of the day from across the health care landscape.

The FDA on Friday approved Pfizer's filgrastim-aafi, a filgrastim biosimilar to Amgen's Neupogen.

There is a concern that mergers and acquisitions in the pharmacy space will lead to decreased competition and loose agreements between companies that will not drive significant outcomes.

Top news of the day from across the health care landscape.

The HIV pandemic will likely continue to be a global challenge for the foreseeable future.

Joy Gilbert, vice president of operations at US Bioservices, gives advice about how specialty pharmacies need to prepare for new drug approvals.

Mapping iron concentration in certain regions of the brain may help predict multiple sclerosis progression risk.

The approval of ivosidenib fills an unmet need for patients with relapsed or refractory acute myeloid leukemia who have an IDH1 genetic mutation.

Gene-editing technology could lead to new targeted therapies and help clinicians catch developing cancers before they metastasize.

Genentech announced that the FDA has granted Breakthrough Therapy Designation to atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) as a first-line treatment for patients with the most common form of liver cancer.

A look at last week's top stories in the world of pharmacy.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

The onus to have properly-trained pharmacists has shifted from the specialty pharmacy to the individual.

New research has associated certain health problems with later diagnosis of multiple sclerosis.

The report compared the tolerability and safety of CGRP inhibitors—erenumab, fremanezumab, and galcanezumab—to no preventive treatment or commonly-used preventive therapies.

Based on 2017 FDA research, the delayed market launch of nine biosimilars represented $4.5 billion in potential savings.

The investigational treatment could benefit patients with amyotrophic lateral sclerosis whose disease is caused by mutations in the SOD1 gene.

Top news of the day from across the health care landscape.

This is the first approval that the FDA has granted as part of its new approaches to streamlining the development and review of oncology drugs.

Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide 10 mg) offers a new treatment option to adults living with HIV.

Study finds that specialty drug coverage policies are mostly inconsistent across health plans and many treatments have multiple restrictions to access.

Supplementation of the protein in the nerve cells prevented nerve degeneration, muscle atrophy, and paralysis in an amyloid lateral sclerosis mouse model.

Top news of the day from across the health care landscape.